A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).-Reference-Cited by-同舟云学术

A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).

Published:2015-05-20 Issue:15_suppl Volume:33 Page:4501-4501
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Petrylak Daniel Peter¹,Powles Thomas²,Bellmunt Joaquim³,Braiteh Fadi S.⁴,Loriot Yohann⁵,Cruz Zambrano Cristina⁶,Burris Howard A.⁷,Kim Joseph W.⁸,Teng Siew-leng Melinda⁹,Bruey Jean-Marie¹⁰,Hegde Priti⁹,Abidoye Oyewale O.¹¹,Vogelzang Nicholas J.¹²

Affiliation:

1. Yale Cancer Center, New Haven, CT

2. Barts Cancer Institute, Barts Health and the Royal Free NHS Trust, London, United Kingdom

3. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

4. Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, NV

5. Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France

6. University Hospital Vall d'Hebron, Barcelona, Spain

7. Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN

8. Yale University Medical Center / Yale Cancer Center, New Haven, CT

9. Genentech, Inc., South San Francisco, CA

10. Genentech, Inc., San Francisco, CA

11. Genentech, San Francisco, CA

12. Carolina Urologic Research Center, The US Oncology Network, Myrtle Beach, SC

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.4501

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The quantity, function and anti-tumor effect of Mucosal associated invariant T cells in patients with bladder cancer;International Immunopharmacology;2024-05

2. Programmed death‐ligand 1 expression and use of immune checkpoint inhibitors among patients with advanced non‐small‐cell lung cancer in a resource‐limited country;Thoracic Cancer;2022-05-03

3. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?;International Immunopharmacology;2022-02

4. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer;JNCI: Journal of the National Cancer Institute;2021-06-07

5. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133);Journal of Clinical Oncology;2021-02-20